The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
Open accessAbstract
BACKGROUND: Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. METHODS: Six randomized, double-blind, controlled clinical trials at five study sites were conducted from April 2004 to February 2017. Active doses of MDMA (75-125 mg, n = 72) or placebo/control doses (0-40 mg, n = 31) were administered to individuals with PTSD during manualized psychotherapy sessions in two or three 8-h sessions spaced a month apart. Three non-drug 90-min therapy sessions preceded the first MDMA exposure, and three to four followed each experimental session. RESULTS: After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups - 22.0 (5.17), P < 0.001]. The between-group Cohen's d effect size was 0.8, indicating a large treatment effect. After two experimental sessions, more participants in the active group (54.2%) did not meet CAPS-IV PTSD diagnostic criteria than the control group (22.6%). Depression symptom improvement on the BDI-II was greatest for the active group compared to the control group, although only trended towards significant group differences [MMRM, estimated mean difference (SE) between groups - 6.0 (3.03), P = 0.053]. All doses of MDMA were well tolerated, with some expected reactions occurring at greater frequency for the active MDMA group during experimental sessions and the 7 days following. CONCLUSIONS: MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD. These studies supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effect sizes for improvements in PTSD and common co-occurring conditions in this pilot study were greater than those found with individually delivered MDMA-facilitated psychotherapy for PTSD (see Mithoefer et al., 2019 for pooled pre- to post-treatment effect in six phase 2 RCTs of approximately d = 1.20).”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDMA-AT has also been most extensively tested in the treatment of post-traumatic stress disorder (PTSD) and has shown to result in large effect size differences compared to placebo controls in Phase II and Phase 3 trials (18–21).”
From MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MDMA (3,4-methylenedioxymethamphetamine) has been used to facilitate an individual therapy for PTSD.”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“In addition, both phase II (19) and the existing phase 3 study (20) suggest excellent safety and low abuse potential when MDMA is used under controlled conditions.”
In the citing paper
“Pooled analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have now shown promising safety and efficacy findings15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
In the citing paper
“Although low-dose MDMA improved blinding in phase 2 studies, it led to decreased effectiveness compared with an inactive placebo in a PTSD population, making it easier to detect a difference between the active and comparator groups15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion
Gronwall, D. M. A. (1977) · Perceptual and Motor Skills · doi:10.2466/pms.1977.44.2.367 · Cited by 2,395 · cited 2×
“Participants completed the PacedAuditory Serial Addition Task (PASAT) (Gronwall 1977) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph 1998) at baseline and 2-month follow-up to determine whether changes in cognitive function had occurred after two sessions…”
MethodA Multidimensional Meta-Analysis of Psychotherapy for PTSD
Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.214 · Cited by 1,938
Kilpatrick, D. G., Resnick, H. S., Milanak, M. E., Miller, M. W., Keyes, K. M., & Friedman, M. J. (2013) · Journal of Traumatic Stress · doi:10.1002/jts.21848 · Cited by 1,929
Clinician-administered PTSD scale: A review of the first ten years of research
Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001) · Depression and Anxiety · doi:10.1002/da.1029 · Cited by 1,903
Posttraumatic stress disorder in the world mental health surveys
Koenen, K. C., Ratanatharathorn, A., Ng, L., McLaughlin, K. A., Bromet, E. J., Stein, D. J., Karam, E. G., Meron Ruscio, A., Benjet, C., Scott, K., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000708 · Cited by 1,453
(2007) · Medical Entomology and Zoology · Cited by 1,118
Prolonged Exposure Therapy for PTSD: Therapist Guide: Emotional processing of traumatic experiences
Foa, E. B., Hembree, E., & Rothbaum, B. (2007) · doi:10.1093/med:psych/9780195308501.001.0001 · Cited by 1,050
Research works printed but not linked: 2
- Grof S (2001) LSD psychotherapy, 4th edn. Multidisciplinary Association for Psychedelic Studies, Ben Lomond, CA
- Kadel R & Kip K (2012). A SAS macro to compute effect size (Cohen’s d) and its confidence interval from raw survey data. In Proceedings of the Annual Southeast SAS Users Group Conference
Cited by
Sorted by citations
Items 101–200 of 359
Lewis, C. R., Tafur, J., Spencer, S., Green, J. M., Harrison, C., Kelmendi, B., Rabin, D. M., Yehuda, R., Yazar‐Klosinski, B., & Cahn, B. R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.959590 · Cited by 32
Potential causal association between gut microbiome and posttraumatic stress disorder
He, Q., Wang, W., Xu, D., Xiong, Y., Tao, C., You, C., Ma, L., & Ma, J. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02765-7 · Cited by 31
Shahrour, G., Sohail, K., Elrais, S., Khan, M. H., Javeid, J., Samdani, K., Mansoor, H., Hussain, S. I., Sharma, D., Ehsan, M., et al. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12485 · Cited by 31
Enhancing equity-oriented care in psychedelic medicine: Utilizing the EQUIP framework
Rea, K., & Wallace, B. B. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103429 · Cited by 32
Whitfield, H. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727572 · Cited by 32
Ching, T. H. W., Williams, M. T., Wang, J. B., Jerome, L., Yazar‐Klosinski, B., Emerson, A., & Doblin, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104052 · Cited by 29
Brewerton, T. D., Lafrance, A., & Mithoefer, M. C. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110367 · Cited by 30
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Sekula, A. D., Downey, L. A., & Puspanathan, P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.813746 · Cited by 30
Íncera-Fernández, D., Román, F. J., & Gámez‐Guadix, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116387 · Cited by 27
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 29
Bahji, A., Lunsky, I. O., Gutiérrez, G., & Vázquez, G. H. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2278586 · Cited by 32
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Kishon, R., Modlin, N. L., Cycowicz, Y. M., Mourtada, H., Wilson, T., Williamson, V., Cleare, A. J., & Rucker, J. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00068-9 · Cited by 29
Exploring the regulatory framework of psychedelics in the US & Europe
Behera, H. K., Joga, R., Yerram, S., Karnati, P., Mergu, T., Gandhi, K., Sowndharya, M., Nathiya, D., Singh, R. P., Srivastava, S., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104242 · Cited by 26
Li, Y., Du, Y., Wang, C., Lu, G., Sun, H., Kong, Y., Wang, W., Lian, B., Li, C., Wang, L., et al. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100503 · Cited by 26
Compassionate use of psychedelics
Greif, A., & Šurkala, M. (2020) · Medicine Health Care and Philosophy · doi:10.1007/s11019-020-09958-z · Cited by 25
Luoma, J. B., Shahar, B., Lear, M. K., Pilecki, B. C., & Wagner, A. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2824 · Cited by 29
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 28
Psychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 24
Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.965641 · Cited by 24
O’Donnell, K. C., Alpert, M., Okano, L., Nicholas, C. R. N., Thomas, C., Poulter, B., Mithoefer, A. T., Mithoefer, M. C., & Marcela Ot’alora, G. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1427531 · Cited by 26
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Feduccia, A. A., Jerome, L., Yazar‐Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021013 · Cited by 24
Bedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 24
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations
Kangaslampi, S., & Zijlmans, J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02310-9 · Cited by 27
Ching, T. H. W. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.017 · Cited by 25
Wang, J. B., Lin, J., Bedrosian, L., Coker, A. R., Jerome, I., Feduccia, A. A., Lilienstein, A., Harrison, C., Heimler, E., Mithoefer, M. C., et al. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211023663 · Cited by 25
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 21
Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 21
Jones, G. M., Arias, D., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-25658-5 · Cited by 23
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee, T. G., Davoudian, P. A., Sanacora, G., & Wilkinson, S. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103818 · Cited by 23
Viña, S. M. (2024) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-024-02023-y · Cited by 21
Vermetten, E. H. G. J. M., & Yehuda, R. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0482-9 · Cited by 21
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
Makunts, T., Jerome, L., Abagyan, R. A., & de Boer, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.824288 · Cited by 20
Avanceña, A. L. V., Kahn, J. G., & Marseille, E. A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01122-0 · Cited by 20
Correia, B., Fernandes, J., Botica, M. J., Ferreira, C., & Quintas, A. (2022) · Medicines · doi:10.3390/medicines9030019 · Cited by 23
Arluk, S., Matar, M. A., Carmi, L., Arbel, O., Zohar, J., Todder, D., & Cohen, H. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01952-8 · Cited by 23
Psychedelic drug use and schizotypy in young adults
Lebedev, A. V., Acar, K., Garzón, B., Almeida, R., Raback, J., Åberg, A., Martinsson, S., Olsson, A., Louzolo, A., Pärnamets, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94421-z · Cited by 19
Psychedelics and workplace harm
Viña, S. M., & Stephens, A. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1186541 · Cited by 19
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P., & Kvamme, T. L. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110843 · Cited by 21
Riaz, K., Suneel, S., Malik, M. H. B. A., Kashif, T., Ullah, I., Waris, A., Nicola, M. D., Mazza, M., Sani, G., Martinotti, G., et al. (2023) · Diseases · doi:10.3390/diseases11040159 · Cited by 19
Psilocybin-assisted therapy for depression: How do we advance the field?
Meikle, S. E., Liknaitzky, P., Rossell, S. L., Ross, M., Strauss, N. H. M., Thomas, N., Murray, G., Williams, M. L., & Castle, D. J. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419888575 · Cited by 19
Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure
Kloft, L., Otgaar, H., Blokland, A., Toennes, S. W., & Ramaekers, J. G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.005 · Cited by 19
MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail
Bedi, G., Cotton, S. M., Guerin, A. A., & Jackson, H. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221127186 · Cited by 18
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 22
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 19
Traumatic Psychedelic Experiences
Calder, A. E., Diehl, V. J., & Hasler, G. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_579 · Cited by 19
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic SymptomsPreprint
Torre, J. T. L., Mahammadli, M., Greenway, K. T., & Williams, M. T. (2022) · Research Square · doi:10.21203/rs.3.rs-1241397/v1 · Cited by 18
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
A review on the mitochondrial toxicity of “ecstasy” (3,4-methylenedioxymethamphetamine, MDMA)
Capela, J. P., & Carvalho, F. D. (2022) · Current Research in Toxicology · doi:10.1016/j.crtox.2022.100075 · Cited by 17
Price, C. M., Feduccia, A. A., & DeBonis, K. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001595 · Cited by 17
MDMA-assisted psychotherapy for borderline personality disorder
Traynor, J. M., Roberts, D. E., Ross, S., Zeifman, R., & Choi-Kain, L. (2022) · Focus · doi:10.1176/appi.focus.20220056 · Cited by 15
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 16
Couple Therapy With MDMA—Proposed Pathways of Action
Wagner, A. C. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.733456 · Cited by 16
FDA rejects ecstasy as a therapy: what’s next for psychedelics?
Reardon, S. (2024) · Nature · doi:10.1038/d41586-024-02597-x · Cited by 15
Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol
Lear, M. K., Smith, S. M., Pilecki, B. C., Stauffer, C. S., & Luoma, J. B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1083354 · Cited by 15
Psychedelics, epilepsy, and seizures: a review
Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326815 · Cited by 14
Diminished psychedelic returns on distress: Marital status and household size
Viña, S. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293675 · Cited by 16
Trauma under psychedelics: how psychoactive substances impact trauma processing
Netzer, O., Magal, N., Stern, Y., Polinsky, T., Gross, R., Admon, R., & Salomon, R. (2025) · World Psychiatry · doi:10.1002/wps.21363 · Cited by 15
Psilocybin for depression: Considerations for clinical trial design
O’Donnell, K. C., Mennenga, S. E., & Bogenschutz, M. P. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.026 · Cited by 18
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J., Luoma, J. B., Nagib, P. B., Pilecki, B. C., & Davis, A. K. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00245 · Cited by 13
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Chambers, R., Stoliker, D., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02206-4 · Cited by 14
Elfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 16
Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022) · Cureus · doi:10.7759/cureus.30919 · Cited by 17
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 12
Kobayashi, I., Mellman, T. A., Cannon, A., Brown, I., Boadi, L., Howell, M. K., Lavela, P., & Sandhu, I. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.12.027 · Cited by 12
Christianity and Psychedelic Medicine: A Pastoral Approach
McCarthy, B. C. (2022) · Christian bioethics Non-Ecumenical Studies in Medical Morality · doi:10.1093/cb/cbac008 · Cited by 14
A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Lewis, B. R., & Byrne, K. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20220088 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001727 · Cited by 13
Religion, Psychedelics, Risky Behavior, and Violence
Viña, S. M. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2346132 · Cited by 12
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder
Choi, C. Q., Johnson, D. E., Chen-Li, D. C. J., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286771 · Cited by 14
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration
Wolfgang, A. S., McClair, V. L., Schnurr, P. P., Holtzheimer, P. E., Woolley, J. D., Stauffer, C. S., Wolf, R. C., States, L. J., Benedek, D. M., Capaldi, V. F., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240751 · Cited by 12
Luoma, J., & Lear, M. K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.733893 · Cited by 11
“In addition, both phase II (19) and the existing phase 3 study (20) suggest excellent safety and low abuse potential whenMDMA is used under controlled conditions.”
BackgroundKvam, T.-M., Goksøyr, I. W., Stewart, L. H., Repantis, D., Røssberg, J. I., & Andreassen, O. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.954388 · Cited by 12
Psychedelic VR Experience: An Exploratory Study on Cosmic Flow
Jung, S., Buruk, O., & Hamari, J. (2022) · International Academic Mindtrek Conference (Mindtrek) · doi:10.1145/3569219.3569391 · Cited by 11
Gao, B., Qu, Y.-C., Cai, M., Zhang, Y.-Y., Lu, H., Li, H.-X., Tang, Y., & Shen, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.006 · Cited by 12
On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli Occupation
Roseman, L., & Karkabi, N. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.718934 · Cited by 11
Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States
Yang, K. H., Kepner, W. E., Nijum, A., Han, B. H., & Palamar, J. J. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001188 · Cited by 11
Elmer, T., Vannoy, T. K., Studerus, E., & Lyubomirsky, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-51355-6 · Cited by 12
Challenges in translational research: MDMA in the laboratory versus therapeutic settings
de Wit, H., Bershad, A. K., & Grob, C. S. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211015221 · Cited by 11
Argento, E., Christie, D., Mackay, L., Callon, C., & Walsh, Z. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716593 · Cited by 12
Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
Jones, G. M., Al‐Suwaidi, M., Castro‐Ramirez, F., McGuire, T. C., Mair, P., & Nock, M. K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1169692 · Cited by 10
Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers
Maia, J. M., de Oliveira, B. S. A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110951 · Cited by 11
Norred, M. A., Zuschlag, Z. D., & Hamner, M. B. (2024) · Drugs · doi:10.1007/s40265-023-01983-5 · Cited by 13
Glynos, N. G., Baker, A., Aday, J. S., Pouyan, N., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2405685 · Cited by 10
Christie, D., Yazar‐Klosinski, B., Nosova, E., Kryskow, P., Siu, W., Lessor, D., & Argento, E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.939302 · Cited by 13
Effect of LSD and music on the time-varying brain dynamics
Adamska-Stolarczyk, I., & Finc, K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06394-8 · Cited by 12
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Viña, S. M. (2024) · Drug Science Policy and Law · doi:10.1177/20503245231225756 · Cited by 10
Ching, T. H. W., Williams, M. T., Reed, S. J., Kisicki, M. D., Wang, J. B., Yazar‐Klosinski, B., Emerson, A., & Doblin, R. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221076993 · Cited by 10
Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
Viña, S. M. (2024) · Psychoactives · doi:10.3390/psychoactives3020019 · Cited by 10
Psychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 11
Beyond Pharmacology: A Narrative Review of Alternative Therapies for Anxiety Disorders
Antos, Z., Zackiewicz, K., Tomaszek, N., Modzelewski, S., & Waszkiewicz, N. (2024) · Diseases · doi:10.3390/diseases12090216 · Cited by 9
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 10
Bhagavan, C., Glue, P., Evans, W., Reynolds, L., Turner, T., King, C., Russell, B. R., Morunga, E., Mills, J. L., Layton, G., et al. (2024) · Trials · doi:10.1186/s13063-024-08174-x · Cited by 10
Positive Affect and Letheby's Naturalization of Psychedelic Therapy
Hoffman, S. (2022) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2022.9285 · Cited by 7
Kolaczynska, K. E., Ducret, P., Trachsel, D., Hoener, M. C., Liechti, M. E., & Luethi, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.03.006 · Cited by 8
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 9
Psychedelics in Psychiatry, the Nursing Influence, and the Future of Psychedelic Therapies
Spotswood, C. J. (2024) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903231222930 · Cited by 9
Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA)
Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001722 · Cited by 9
Sebben, B., Stone, J., Sarris, J. J., Perkins, D., Mallie, K., Barnett, S., Ruffell, S., & Beesley, V. L. (2024) · Australian and New Zealand Journal of Public Health · doi:10.1016/j.anzjph.2024.100200 · Cited by 7
Metadata
- Authors
- Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R.
- Affiliations
- Medical University of South Carolina (US)
- Multidisciplinary Association for Psychedelic Studies (US)
- University of British Columbia, Okanagan Campus (CA)
- Stanford Medicine (US)
- Corresponding author
- Feduccia, Allison A.
- Venue
- Psychopharmacology
- Published
- 2019-05-07
- Volume
- 236
- Issue
- 9
- Pages
- 2735-2745
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC6695343
- OpenAlex
- W2944263526
- Cited by
- 359
- References
- 39
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 54 · 2023: 76 · 2022: 78 · 2021: 56 · 2020: 38 · 2019: 11
- FWCI
- 53.72
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-08-10)
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Multidisciplinary Association for Psychedelic Studies (X)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, phase 3 trial design, treatment efficacy, depression symptom improvement, tolerability, breakthrough therapy designation
- MeSH terms
- Adult, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychotherapy, Stress Disorders, Post-Traumatic, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
